Is Syndax Pharmaceuticals Inc (SNDX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 17.7% / 30% | 21.3% / 30% | 3.6% / 30% | 13.19% / 5% | ✗ NOT HALAL |
| DJIM | 17.7% / 33% | 21.3% / 33% | 3.6% / 33% | 13.19% / 5% | ✗ NOT HALAL |
| MSCI | 65.2% / 33% | 78.1% / 33% | 13.3% / 33% | 13.19% / 5% | ✗ NOT HALAL |
| S&P | 17.7% / 33% | 21.3% / 33% | 3.6% / 33% | 13.19% / 5% | ✗ NOT HALAL |
| FTSE | 65.2% / 33% | 78.1% / 33% | 13.3% / 50% | 13.19% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -54.2% | |
| Operating Margin | -91.6% | |
| Net Margin | -165.6% | |
| Return on Equity (ROE) | -161.8% | |
| Return on Assets (ROA) | -27.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$323M |
| Free Cash Flow | -$323M |
| Total Debt | $345M |
| Debt-to-Equity | 534.5 |
| Current Ratio | 4.4 |
| Total Assets | $530M |
Price & Trading
| Last Close | $24.70 |
| 50-Day MA | $21.81 |
| 200-Day MA | $16.80 |
| Avg Volume | 1.3M |
| Beta | 0.5 |
|
52-Week Range
$8.58
| |
About Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Syndax Pharmaceuticals Inc (SNDX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Syndax Pharmaceuticals Inc is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Syndax Pharmaceuticals Inc's debt ratio?
Syndax Pharmaceuticals Inc's debt ratio is 17.7% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 65.2%.
What are Syndax Pharmaceuticals Inc's key financial metrics?
Syndax Pharmaceuticals Inc has a market capitalization of $2.1B, and revenue of $172M. The company maintains a gross margin of -54.2% and a net margin of -165.6%. Return on equity stands at -161.8%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.